Drug Repositioning for Gynecologic Tumors: A New Therapeutic Strategy for Cancer

The goals of drug repositioning are to find a new pharmacological effect of a drug for which human safety and pharmacokinetics are established and to expand the therapeutic range of the drug to another disease. Such drug discovery can be performed at low cost and in the short term based on the resul...

Full description

Saved in:
Bibliographic Details
Main Authors: Kouji Banno, Miho Iida, Megumi Yanokura, Haruko Irie, Kenta Masuda, Yusuke Kobayashi, Eiichiro Tominaga, Daisuke Aoki
Format: Article
Language:English
Published: Wiley 2015-01-01
Series:The Scientific World Journal
Online Access:http://dx.doi.org/10.1155/2015/341362
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832550624518995968
author Kouji Banno
Miho Iida
Megumi Yanokura
Haruko Irie
Kenta Masuda
Yusuke Kobayashi
Eiichiro Tominaga
Daisuke Aoki
author_facet Kouji Banno
Miho Iida
Megumi Yanokura
Haruko Irie
Kenta Masuda
Yusuke Kobayashi
Eiichiro Tominaga
Daisuke Aoki
author_sort Kouji Banno
collection DOAJ
description The goals of drug repositioning are to find a new pharmacological effect of a drug for which human safety and pharmacokinetics are established and to expand the therapeutic range of the drug to another disease. Such drug discovery can be performed at low cost and in the short term based on the results of previous clinical trials. New drugs for gynecologic tumors may be found by drug repositioning. For example, PPAR ligands may be effective against ovarian cancer, since PPAR activation eliminates COX-2 expression, arrests the cell cycle, and induces apoptosis. Metformin, an antidiabetic drug, is effective for endometrial cancer through inhibition of the PI3K-Akt-mTOR pathway by activating LKB1-AMPK and reduction of insulin and insulin-like growth factor-1 due to AMPK activation. COX-2 inhibitors for cervical cancer may also be examples of drug repositioning. PGE2 is induced in the arachidonate cascade by COX-2. PGE2 maintains high expression of COX-2 and induces angiogenic factors including VEGF and bFGF, causing carcinogenesis. COX-2 inhibitors suppress these actions and inhibit carcinogenesis. Combination therapy using drugs found by drug repositioning and current anticancer drugs may increase efficacy and reduce adverse drug reactions. Thus, drug repositioning may become a key approach for gynecologic cancer in drug discovery.
format Article
id doaj-art-6287041168274984a798f597261dea0d
institution Kabale University
issn 2356-6140
1537-744X
language English
publishDate 2015-01-01
publisher Wiley
record_format Article
series The Scientific World Journal
spelling doaj-art-6287041168274984a798f597261dea0d2025-02-03T06:06:22ZengWileyThe Scientific World Journal2356-61401537-744X2015-01-01201510.1155/2015/341362341362Drug Repositioning for Gynecologic Tumors: A New Therapeutic Strategy for CancerKouji Banno0Miho Iida1Megumi Yanokura2Haruko Irie3Kenta Masuda4Yusuke Kobayashi5Eiichiro Tominaga6Daisuke Aoki7Department of Obstetrics and Gynecology, School of Medicine, Keio University, Tokyo 160-0016, JapanDepartment of Obstetrics and Gynecology, School of Medicine, Keio University, Tokyo 160-0016, JapanDepartment of Obstetrics and Gynecology, School of Medicine, Keio University, Tokyo 160-0016, JapanDepartment of Obstetrics and Gynecology, School of Medicine, Keio University, Tokyo 160-0016, JapanDepartment of Obstetrics and Gynecology, School of Medicine, Keio University, Tokyo 160-0016, JapanDepartment of Obstetrics and Gynecology, School of Medicine, Keio University, Tokyo 160-0016, JapanDepartment of Obstetrics and Gynecology, School of Medicine, Keio University, Tokyo 160-0016, JapanDepartment of Obstetrics and Gynecology, School of Medicine, Keio University, Tokyo 160-0016, JapanThe goals of drug repositioning are to find a new pharmacological effect of a drug for which human safety and pharmacokinetics are established and to expand the therapeutic range of the drug to another disease. Such drug discovery can be performed at low cost and in the short term based on the results of previous clinical trials. New drugs for gynecologic tumors may be found by drug repositioning. For example, PPAR ligands may be effective against ovarian cancer, since PPAR activation eliminates COX-2 expression, arrests the cell cycle, and induces apoptosis. Metformin, an antidiabetic drug, is effective for endometrial cancer through inhibition of the PI3K-Akt-mTOR pathway by activating LKB1-AMPK and reduction of insulin and insulin-like growth factor-1 due to AMPK activation. COX-2 inhibitors for cervical cancer may also be examples of drug repositioning. PGE2 is induced in the arachidonate cascade by COX-2. PGE2 maintains high expression of COX-2 and induces angiogenic factors including VEGF and bFGF, causing carcinogenesis. COX-2 inhibitors suppress these actions and inhibit carcinogenesis. Combination therapy using drugs found by drug repositioning and current anticancer drugs may increase efficacy and reduce adverse drug reactions. Thus, drug repositioning may become a key approach for gynecologic cancer in drug discovery.http://dx.doi.org/10.1155/2015/341362
spellingShingle Kouji Banno
Miho Iida
Megumi Yanokura
Haruko Irie
Kenta Masuda
Yusuke Kobayashi
Eiichiro Tominaga
Daisuke Aoki
Drug Repositioning for Gynecologic Tumors: A New Therapeutic Strategy for Cancer
The Scientific World Journal
title Drug Repositioning for Gynecologic Tumors: A New Therapeutic Strategy for Cancer
title_full Drug Repositioning for Gynecologic Tumors: A New Therapeutic Strategy for Cancer
title_fullStr Drug Repositioning for Gynecologic Tumors: A New Therapeutic Strategy for Cancer
title_full_unstemmed Drug Repositioning for Gynecologic Tumors: A New Therapeutic Strategy for Cancer
title_short Drug Repositioning for Gynecologic Tumors: A New Therapeutic Strategy for Cancer
title_sort drug repositioning for gynecologic tumors a new therapeutic strategy for cancer
url http://dx.doi.org/10.1155/2015/341362
work_keys_str_mv AT koujibanno drugrepositioningforgynecologictumorsanewtherapeuticstrategyforcancer
AT mihoiida drugrepositioningforgynecologictumorsanewtherapeuticstrategyforcancer
AT megumiyanokura drugrepositioningforgynecologictumorsanewtherapeuticstrategyforcancer
AT harukoirie drugrepositioningforgynecologictumorsanewtherapeuticstrategyforcancer
AT kentamasuda drugrepositioningforgynecologictumorsanewtherapeuticstrategyforcancer
AT yusukekobayashi drugrepositioningforgynecologictumorsanewtherapeuticstrategyforcancer
AT eiichirotominaga drugrepositioningforgynecologictumorsanewtherapeuticstrategyforcancer
AT daisukeaoki drugrepositioningforgynecologictumorsanewtherapeuticstrategyforcancer